|Bid||0.00 x 800|
|Ask||0.00 x 1200|
|Day's Range||21.41 - 21.50|
|52 Week Range||21.15 - 24.65|
|PE Ratio (TTM)||251.88|
|Expense Ratio (net)||0.30%|
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products. In the second quarter, the segment’s revenue grew 3% YoY (year-over-year) at constant exchange rates to ~1.8 billion British pounds, as shown in the chart below. GlaxoSmithKline bought out Novartis’s (NVS) stake in the companies’ consumer healthcare joint venture on June 1.
As we’ve already seen, Novartis (NVS) reported a 7% growth in operating revenues to ~$13.16 billion in Q2 2018. That compares to revenues of ~$12.24 billion in Q2 2017.
On May 15, leading pharmaceutical company Novartis (NVS) acquired AveXis, a US-based clinical-stage gene therapy company. This transaction strengthens Novartis’s position as a leader in gene therapy and neuroscience. The chart below summarizes the deal.
Analysts expect AstraZeneca (AZN) to report EPS (earnings per share) of $0.60 on revenue of $5.3 billion in the first quarter, a 2.3% fall compared to its revenue of $5.4 billion during the first quarter of 2017. AstraZeneca’s stock price has risen nearly 7.1% over the last 12 months and ~4.9% year-to-date.
GlaxoSmithKline’s (GSK) Consumer Healthcare business includes various products for oral health, wellness, nutrition, and skin health. The consumer healthcare business reported revenues of ~2.0 billion pounds in 1Q18, a ~3% decrease compared to 1Q17.
Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.
Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company that specializes in researching, developing, manufacturing, and marketing a broad range of healthcare products.
Sanofi (SNY) is consistently investing in and focusing on its R&D (research and development) strategy. The company has a number of key technology platforms driving its multitargeting strategy in R&D. Sanofi spends ~15% of its total sales on R&D. In recent years, Sanofi has transformed its R&D approach and has shifted toward biologics and combination therapies.
On October 20, 2017, the U.S. Food and Drug Administration (or FDA) approved GlaxoSmithKline’s (GSK) Zoster vaccine recombinant and adjuvanted vaccine, Shingrix, as a preventive measure against herpes zoster infection of shingles for adults over 50 years. This approval was based on solid efficacy, safety, and immunogenicity demonstrated by this non-live, recombinant subunit vaccine phase three program consisting of around 38,000 people.
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
In 1H17, Teva Pharmaceutical's (TEVA) respiratory franchise reported revenues of ~$626 million, or ~8% lower YoY (year-over-year).
GlaxoSmithKline's (GSK) vaccine business includes meningitis vaccines, influenza vaccines, and the established vaccines in its portfolio.
Novartis is focused on integrated drug development as well as centralized operations, and its new organizational structure has proven to be beneficial.
Sanofi’s (SNY) established products contributed over 29.5% of its total revenue in 2Q17. Established product revenue, which fell 2.3% at constant exchange rates in 2Q17, stood at 2.6 billion euros. Lower…...